Clinical Trials Links:
Practice Information:
The following study is open to patients with atypical or malignant meningiomas that
have recurred after radiation therapy:
Recurrent Atypical or Malignant Meningioma
Phase II Study of Thalidomide in Atypical or Malignant Meningioma
Eligibility: Recurrent atypical or malignant meningioma following completion of radiation therapy. Not a candidate for gross total tumor resection or for radiosurgery.
Protocol: Thalidomide is administered daily until tumor recurrence.